Literature DB >> 1594045

Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.

V L Tybulewicz1, M L Tremblay, M E LaMarca, R Willemsen, B K Stubblefield, S Winfield, B Zablocka, E Sidransky, B M Martin, S P Huang.   

Abstract

Gaucher's disease is the most prevalent lysosomal storage disorder in humans and results from an autosomally inherited deficiency of the enzyme glucocerebrosidase (beta-D-glucosyl-N-acylsphingosine glucohydrolase), which is responsible for degrading the sphingolipid glucocerebroside. An animal model for Gaucher's disease would be important for investigating its phenotypic diversity and pathogenesis and for evaluating therapeutic approaches. A naturally occurring canine model has been reported but not propagated. Attempts to mimic the disease in animals by inhibiting glucocerebrosidase have been inadequate. Here we generate an animal model for Gaucher's disease by creating a null allele in embryonic stem cells through gene targeting and using these genetically modified cells to establish a mouse strain carrying the mutation. Mice homozygous for this mutation have less than 4% of normal glucocerebrosidase activity, die within twenty-four hours of birth and store glucocerebroside in lysosomes of cells of the reticuloendothelial system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594045     DOI: 10.1038/357407a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  86 in total

1.  Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase.

Authors:  Lei Bi; Ichiro Okabe; David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2002-03       Impact factor: 2.957

Review 2.  Parkinson's disease pathogenesis from the viewpoint of small fish models.

Authors:  Hideaki Matsui; Ryosuke Takahashi
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

3.  Perinatal lethal Gaucher disease.

Authors:  Nishad Plakkal; Amuchou Singh Soraisham; Junya Jirapradittha; Alfredo Pinto-Rojas
Journal:  Indian J Pediatr       Date:  2010-10-06       Impact factor: 1.967

Review 4.  Glycosphingolipidoses: beyond the enzymatic defect.

Authors:  Annick Raas-Rothschild; Irene Pankova-Kholmyansky; Yaacov Kacher; Anthony H Futerman
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 5.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

6.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

Review 7.  Glycosphingolipid degradation and animal models of GM2-gangliosidoses.

Authors:  T Kolter; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

8.  The non-lysosomal β-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi.

Authors:  Heinz G Körschen; Yildiz Yildiz; Diana Nancy Raju; Sophie Schonauer; Wolfgang Bönigk; Vera Jansen; Elisabeth Kremmer; U Benjamin Kaupp; Dagmar Wachten
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 9.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

10.  Metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is required for embryonic development in the mouse: implications for Gaucher disease.

Authors:  P Bornstein; C E McKinney; M E LaMarca; S Winfield; T Shingu; S Devarayalu; H L Vos; E I Ginns
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.